Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Longeveron LLC

Healthcare US LGVN

0.73USD
-0.07(8.75%)

Last update at 2026-06-05T20:10:00Z

Day Range

0.720.80
LowHigh

52 Week Range

1.0340.00
LowHigh

Fundamentals

  • Previous Close 0.80
  • Market Cap6.79M
  • Volume306047
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.06000M
  • Revenue TTM0.71M
  • Revenue Per Share TTM0.33
  • Gross Profit TTM 0.50M
  • Diluted EPS TTM-9.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.83500M -17.04500M -3.72081M -2.95988M -6.33680M
Minority interest - - - - -
Net income -19.62700M -17.16400M -3.79122M -2.99551M -6.33680M
Selling general administrative 8.12M 10.73M 2.73M 2.77M 3.12M
Selling and marketing expenses 1.05M 0.22M 0.20M 0.19M 0.05M
Gross profit 0.50M 0.59M 1.83M 1.75M 0.68M
Reconciled depreciation 0.89M 0.91M 0.79M 0.77M 0.75M
Ebit -18.04300M -17.45600M -3.77828M -2.99811M -6.33680M
Ebitda -17.43700M -16.42700M -2.92883M -2.19087M -5.59102M
Depreciation and amortization 0.61M 1.03M 0.85M 0.81M 0.75M
Non operating income net other -0.79200M 0.41M - - -
Operating income -18.04300M -17.45600M -3.77828M -2.99811M -6.36062M
Other operating expenses 19.27M 18.76M 9.41M 8.64M 8.50M
Interest expense -0.28700M 0.00400M 0.00654M 0.00017M 0.00000M
Tax provision - - - - -
Interest income - - 0.00014M 0.00294M 0.02M
Net interest income 0.00000M -0.00400M -0.00640M 0.00277M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.79M 0.12M 0.07M 0.04M 0.02M
Total revenue 1.22M 1.31M 5.63M 5.64M 2.13M
Total operating expenses 18.54M 18.05M 5.60M 4.75M 7.04M
Cost of revenue 0.72M 0.72M 3.80M 3.89M 1.45M
Total other income expense net -0.79200M 0.41M 0.06M 0.04M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -18.83500M -17.04500M -3.72081M -2.95988M -6.33680M
Net income applicable to common shares -18.83500M -17.04500M -3.72081M -2.95988M -6.33680M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.18M 27.41M 42.77M 9.24M 10.58M
Intangible assets 2.29M 2.41M 2.33M 1.55M 1.48M
Earning assets - - - - -
Other current assets 0.38M 0.40M 0.28M 0.61M 0.05M
Total liab 5.34M 6.91M 5.31M 7.28M 6.14M
Total stockholder equity 6.84M 20.50M 37.45M 1.96M 4.45M
Deferred long term liab - - - - -
Other current liab 2.15M 2.05M 1.33M 1.54M 0.30M
Common stock 0.03M 0.02M 0.02M 2.06M 4.60M
Capital stock 0.03M 0.02M 0.02M - -
Retained earnings -84.98400M -62.77300M -43.93800M - -
Other liab - - 5.31M - -
Good will - - - - -
Other assets - 0.24M 2.33M 0.00225M 0.25M
Cash 4.95M 10.50M 25.66M 0.82M 1.87M
Cash and equivalents - - - - -
Total current liabilities 3.89M 4.87M 2.71M 3.83M 2.49M
Current deferred revenue 0.51M 0.51M 0.20M 0.01000M 0.54M
Net debt -2.90800M -7.89800M -22.51600M 3.33M 2.27M
Short term debt 0.59M 0.56M 0.54M 0.69M 0.49M
Short long term debt - - - 0.18M -
Short long term debt total 2.04M 2.60M 3.14M 4.14M 4.14M
Other stockholder equity 91.80M 83.61M 81.37M 1.96M 6.55M
Property plant equipment - 2.95M 3.06M 5.67M 6.48M
Total current assets 5.85M 19.66M 35.38M 1.85M 2.37M
Long term investments - - - - -
Net tangible assets - 18.09M 35.12M 0.41M 2.96M
Short term investments 0.41M 9.15M 9.38M - -
Net receivables 0.11M 0.22M 0.06M 0.42M 0.45M
Long term debt - 2.04M 2.60M 0.31M -
Inventory - -0.62200M 0.28M - -
Accounts payable 0.64M 1.75M 0.65M 1.59M 1.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10000M -0.35700M - - -2.10118M
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00500M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -62.77300M -43.93800M - -
Treasury stock - -0.10000M -0.10000M - -
Accumulated amortization - - - - -
Non currrent assets other 0.09M 2.40M 0.18M 0.18M 0.25M
Deferred long term asset charges - - - - -
Non current assets total 6.33M 7.75M 7.39M 7.39M 8.21M
Capital lease obligations 2.04M 2.60M 3.14M 3.65M 4.14M
Long term debt total - 2.04M 2.60M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.67700M -9.47100M -0.26150M -0.12505M -0.21168M
Change to liabilities 0.43M -1.15900M -0.40086M -0.12013M 0.10M
Total cashflows from investing activities -0.67700M -10.69600M -0.26150M -0.12505M -0.21168M
Net borrowings - -0.18800M 0.49M 0.49M 0.49M
Total cash from financing activities -0.50900M 45.17M 1.58M 0.35M 1.35M
Change to operating activities -1.01100M -0.69900M 0.86M 0.23M -0.11563M
Net income -18.83500M -17.04500M -3.72081M -2.95988M -6.33680M
Change in cash -15.15500M 24.84M -1.05007M -2.16585M -4.03506M
Begin period cash flow 25.66M 0.82M 1.87M 4.03M 8.07M
End period cash flow 10.50M 25.66M 0.82M 1.87M 4.03M
Total cash from operating activities -13.96900M -9.63600M -2.36390M -2.39081M -5.17837M
Issuance of capital stock 0.00000M 45.19M 1.10M - -
Depreciation 0.89M 0.91M 0.79M 0.77M 0.75M
Other cashflows from investing activities -0.10800M -0.89500M - - -
Dividends paid - - - - -
Change to inventory - - -0.03081M - -
Change to account receivables -0.16400M 0.37M 0.03M -0.45146M -0.45146M
Sale purchase of stock 0.00200M 45.81M - - -
Other cashflows from financing activities -0.50900M 0.17M 0.50M 0.35M 1.35M
Change to netincome 2.64M 8.01M 0.08M 0.14M 0.42M
Capital expenditures 0.86M 1.31M 0.26M 0.13M 0.21M
Change receivables -0.16400M 0.37M - - -
Cash flows other operating 1.06M -0.72500M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -15.15500M 24.84M - - -
Change in working capital 0.24M -1.09000M 0.49M -0.33661M -0.01122M
Stock based compensation 2.34M 7.74M 0.04M 0.14M 0.42M
Other non cash items 1.40M -0.15500M 0.04M 2.08M -
Free cash flow -14.82500M -10.94600M -2.62540M -2.51585M -5.39006M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LGVN
Longeveron LLC		 -0.07 8.75% 0.73 - - 7.57 0.80 2.88 -0.1018
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron LLC

Life Science and Technology Park, Miami, FL, United States, 33136

Key Executives

Name Title Year Born
Dr. Joshua Michael Hare FACC, M.D. Co-Founder, Chief Science Officer & Chairman 1963
Mr. James Clavijo CPA CFO & Treasurer 1966
Mr. Paul T. Lehr J.D. International Exec. Director, Gen. Counsel & Sec. 1968
Dr. Kwan-Hong Min M.D., Ph.D. Chief Medical Officer & Interim CEO 1967
Dr. Dan Gincel Ph.D. Sr. VP of Strategic Collaborations & Scientific Affairs 1971
Mr. Mohamed Wa'el Ahmed Hashad CEO & Director 1962
Ms. Lisa A. Locklear M.B.A. Executive VP & CFO 1962
Mr. Paul T. Lehr J.D. International Executive Director, General Counsel & Secretary 1968
Dr. Dan Gincel Ph.D. Senior Vice President of Strategic Collaborations & Scientific Affairs 1971
Dr. Nataliya Agafanova M.D. Chief Medical Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.